Search Result

Results for "

HSCs inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (4) Atg8/LC3 (1) ATP Synthase (1) Autophagy (2) Caspase (1) CDK (6) Ceramidase (1) Collagen (1) CXCR (3) EGFR (1) Endogenous Metabolite (1) ERK (1) Galectin (1) Histone Methyltransferase (1) HIV (3) HOXA (2) HSP (3) Integrin (1) Isotope-Labeled Compounds (1) JAK (1) MDM-2/p53 (1) MEK (1) MMP (2) mTOR (1) Nuclear Hormone Receptor 4A/NR4A (1) P2Y Receptor (1) p62 (1) Parasite (1) Phosphatase (1) PKA (1) Raf (2) Ras (1) Reference Standards (2) STAT (1) TGF-beta/Smad (3) TGF-β Receptor (1) VD/VDR (3)
By Research Areas:	Cancer (17) Cardiovascular Disease (1) Endocrinology (4) Infection (4) Inflammation/Immunology (14) Metabolic Disease (3) Neurological Disease (3)

By Targets:

Apoptosis (4)

Atg8/LC3 (1)

ATP Synthase (1)

Autophagy (2)

Caspase (1)

CDK (6)

Ceramidase (1)

Collagen (1)

CXCR (3)

EGFR (1)

Endogenous Metabolite (1)

ERK (1)

Galectin (1)

Histone Methyltransferase (1)

HIV (3)

HOXA (2)

HSP (3)

Integrin (1)

Isotope-Labeled Compounds (1)

JAK (1)

MDM-2/p53 (1)

MEK (1)

MMP (2)

mTOR (1)

Nuclear Hormone Receptor 4A/NR4A (1)

P2Y Receptor (1)

p62 (1)

Parasite (1)

Phosphatase (1)

PKA (1)

Raf (2)

Ras (1)

Reference Standards (2)

STAT (1)

TGF-beta/Smad (3)

TGF-β Receptor (1)

VD/VDR (3)

By Research Areas:

Cancer (17)

Cardiovascular Disease (1)

Endocrinology (4)

Infection (4)

Inflammation/Immunology (14)

Metabolic Disease (3)

Neurological Disease (3)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10046

Plerixafor Maximum Cited Publications 102 Publications Verification AMD 3100; JM3100; SID791	CXCR HIV	Infection Inflammation/Immunology Endocrinology Cancer
Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC₅₀ of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC₅₀ of 1-10 nM .

HY-10941

VER-155008 40+ Cited Publications	HSP Autophagy	Neurological Disease Cancer
VER-155008 is an inhibitor of Hsp70, with IC₅₀s of 0.5 μM, 2.6 μM, and 2.6 μM for Hsp70, Hsc70 and Grp7, respectively, and with a K_d of 0.3 μM for Hsp70.

HY-15098

Apoptozole 10+ Cited Publications Apoptosis Activator VII	HSP Apoptosis	Cancer
Apoptozole (Apoptosis Activator VII) is an inhibitor of the ATPase domain of *Hsc70* and Hsp70, with K_ds of 0.21 and 0.14 μM, respectively, and can induce apoptosis.

HY-134259

MEISi-2	HOXA	Cancer
MEISi-2 is a selective inhibitor of MEIS, a key regulator of hematopoietic stem cell (HSC) self-renewal. MEISi-2 is developed for the research of cardiac injuries, hematopoiesis issues, bone marrow transplantations, and cancer .

HY-134258

MEISi-1	HOXA	Cardiovascular Disease Others Cancer
MEISi-1 is a homeodomain inhibitor of small molecule MEIS1 protein. MEISi-1 significantly inhibited the activity of luciferase reporter genes containing MEIS binding sites (TGACAG) and induced self-renewal of mouse and human HSCS in vitro and in vivo. MEISi-1 can be used for research in blood diseases, heart regeneration and cancer .

HY-129453

BOP sodium	Integrin	Inflammation/Immunology
BOP sodium is a potent and selective dual α9β1/α4β1 integrin inhibitor with K_d values in the picomolar range. BOP sodium shows the rapid and preferential mobilization of hematopoietic stem cell (HSC) and progenitors. BOP sodium has little inhibitory activity on α4β7, α1β1, α2β1, and α5β1, αIIBβ3 integrins .

HY-100791

NSC23005 sodium 1 Publications Verification	CDK	Cancer
NSC23005 sodium is a novel and effective p18 inhibitor (ED₅₀=5.21 nM) in promoting Hematopoietic stem cells (HSCs) expansion in both murine and human models.

HY-123535

P18IN003	CDK	Inflammation/Immunology
P18IN003 is a potent p18(INK4C) inhibitor andspecifically block the activity of p18 protein. P18IN003 has the potential to be aneffective chemical agent for therapeutic expansion of HSC .

HY-155786

3,7-DMF	TGF-beta/Smad	Others
3,7-DMF is an orally active inhibitor of TGF-β1-induced activation of HSCs. 3,7-DMF induces antioxidant genes and quenches ROS away, which can be used to study liver fibrosis .

HY-175496

Acid Ceramidase-IN-3	Ceramidase	Inflammation/Immunology
Acid Ceramidase-IN-3 is a acid ceramidase (aCDase) inhibitor. Acid Ceramidase-IN-3 inhibits the enzymatic activity of aCDase with a pIC ₅₀ of 8.5 in enzymatic assays and 6.8 in A375 melanoma cellular assays. Acid Ceramidase-IN-3 promotes HSC inactivation, as measured by a dose-dependent reduction in COL1A1 and ACTA2. Acid Ceramidase-IN-3 inhibits aCDase activity in HSCs, promotes HSC inactivation and suppresses YAP/TAZ nuclear localization. Acid Ceramidase-IN-3 increases Dynein/Kinesin (NDE1, NDEL1. KIF3B, KIF15) while decreases several proteins involved with signaling pathway (SARM1, RGAP1, PDGF-D,PDGFR-B). Acid Ceramidase-IN-3 can be used for the study of fibrotic diseases .

HY-108420

INK4C-IN-2 1 Publications Verification	CDK	Cancer
INK4C-IN-2 is a p18 ^INK4C inhibitor. NK4C-IN-2 promotes hematopoietic stem cells (HSCs) division by inhibiting INK4C and activating CDK4/6, with an ED₅₀ of 5.21 nM. INK4C-IN-2 shows no cytotoxic to normal 32D cells, HSCs, leukemia cell lines and myeloma cell lines .

HY-120942

XIE18-6	CDK	Cancer
XIE18-6 is a potent INK4C (p18) inhibitor. XIE18-6 shows potent bioactivity in hematopoietic stem cells (HSCs) expansion with an ED₅₀ of 105.5 nM .

HY-10046S

Plerixafor-d4	Isotope-Labeled Compounds CXCR HIV	Infection Inflammation/Immunology Endocrinology Cancer
Plerixafor-d₄ is the deuterium labeled Plerixafor. Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC₅₀ of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC₅₀ of 1-10 nM .

HY-179133

HDB-1	P2Y Receptor PKA Raf MEK ERK	Inflammation/Immunology
HDB-1 is a selective inhibitor of the P2Y14 receptor (P2Y14R) with an IC₅₀ of 26 pM. HDB-1 shows no significant inhibition on P2Y1R, P2Y2R, P2Y4R, P2Y6R, and P2Y12R. HDB-1 blocks the activation of hepatic stellate cells (HSC) by inhibiting the PKA/Raf1/MEK/ERK signaling pathway mediated by P2Y14R, thereby alleviating the core pathological process of liver fibrosis. HDB-1 can be used for the study of liver fibrosis .

HY-131831A

6-Bn-ADP sodium N6-benzyl ADP sodium	ATP Synthase	Cancer
6-Bn-ADP (N6-benzyl ADP) sodium is a derivative of Adenosine 5'-diphosphate (ADP) (HY-W010918) that inhibits ATP hydrolysis. 6-Bn-ADP sodium inhibits the ATPase activities of Mortalin, Hsc70, and Hsp70 protein with K_is of 86.51 μM, 294.5 μM, and 1612 μM, respectively .

HY-10046R

Plerixafor (Standard) AMD 3100 (Standard); JM3100 (Standard); SID791 (Standard)	Reference Standards CXCR HIV	Infection Inflammation/Immunology Endocrinology Cancer
Plerixafor (Standard) is the analytical standard of Plerixafor. This product is intended for research and analytical applications. Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC₅₀ of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC₅₀ of 1-10 nM .

HY-W414644

Fluacrypyrim	Parasite STAT Phosphatase MDM-2/p53 Apoptosis	Infection Neurological Disease Inflammation/Immunology Cancer
Fluacrypyrim, a Miticide, is a STAT3 inhibitor. Fluacrypyrim significantly increases the protein tyrosine phosphatases(PTPs) activity. Fluacrypyrim inhibits the growth of leukemia cells by a predominant G1 arrest with significant decrease of the protein and mRNA levels of cyclin D1. Fluacrypyrim selectively inhibits STAT3 signaling, inducing growth arrest and apoptosis in STAT3-dependent cancer cells. Fluacrypyrim mitigates IR-induced hematopoietic system injury mainly by preventing apoptosis in the HSCs. Fluacrypyrim demonstrates significant analgesic and anti-inflammatory effects by inhibiting uterine smooth muscle contraction and inflammatory responses .

HY-115893A

P18IN005 hydrochloride	CDK	Cancer
P18IN005 hydrochloride is a novel inhibitor of p18, exhibiting potent activity in negatively regulating haematopoietic stem cell (HSC) self-renewal. P18IN005 hydrochloride has been shown to be more effective than p27 in inhibiting HSC self-renewal in mouse models. P18IN005 hydrochloride promotes the expansion of functional HSCs in short-term cultures. P18IN005 hydrochloride serves as a valuable tool for dissecting the signaling pathways involved in stem cell self-renewal.

HY-116664

DPQZ	Apoptosis Ras Raf Caspase	Cancer
DPQZ is an anti-tubulin agent that inhibits cell separation and induces cell cycle arrest at the G2/M phase. In addition, DPQZ induces caspase-dependent apoptosis of HSC-3 cells by inhibiting Ras/Raf and activating MAP kinase. DPQZ can be used in the study of oral cancer .

HY-111244

DCB-3503	CDK HSP	Others
DCB-3503 is an allosteric modulator of heat shock cognate protein *HSC70* and an inhibitor of Cyclin D1. DCB-3503 inhibits Cyclin D1 translation by allosterically modulating the ATPase and chaperone activities of HSC70. DCB-3503 may inhibit malignancies such as hepatocellular carcinoma or breast cancer with elevated expression of cyclin D1 .

HY-119582

Safironil	MMP	Inflammation/Immunology
Safironil is an antifibrotic compound. Safironil is a competitive inhibitor of collagen protein synthesis. Safironil reduces liver fibrogenesis by inhibiting HSC activation .

HY-162147

Nur77 modulator 3	Nuclear Hormone Receptor 4A/NR4A Autophagy mTOR TGF-beta/Smad Atg8/LC3 p62	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Nur77 modulator 3 is a Nur77 modulator. Nur77 modulator 3 induces Nur77 expression, inhibits hepatic stellate cells (HSCs) activation, and reduces extracellular matrix (ECM) deposition. Nur77 modulator 3 enhances Nur77-denpendent autophagic flux and significantly inhibits the mTORC1 signaling pathway. Nur77 modulator 3 ameliorates HSCs activation, inflammation and hepatic fibrosis in vivo .

HY-149899

VDR agonist 2	VD/VDR	Others
VDR agonist 2 (compound 16i) is a VDR (vitamin D receptor) agonist that can effectively inhibit TGF-β1-induced activation of hepatic stellate cells (HSC). VDR agonist 2 has significant anti-hepatic fibrosis effects both in vitro and in vivo .

HY-172087

VDR agonist 3	VD/VDR	Inflammation/Immunology
VDR agonist 3 (Compound E15) is a potent vitamin D receptor (VDR) agonist. VDR agonist 3 can effectively inhibit HSC activation through VDR. VDR agonist 3 significantly reduces liver fibrosis without causing hypercalcemia in a CCl4-induced mouse liver fibrosis model .

HY-170543

Dual Galectin-3/EGFR-IN-1	Galectin EGFR Apoptosis	Inflammation/Immunology
Dual Galectin-3/EGFR-IN-1 (Compound 29) is the dual inhibitor for Galectin-3 and EGFR with the K_D of 52.29 μM and 3.31 μM. Dual Galectin-3/EGFR-IN-1 inhibits TGF-β-induced hepatic stellate cell (HSCs) activation, induces apoptosis in LX-2 cell, and exhibits anti-liver fibrotic efficacy .

HY-178328

VDR agonist 4	VD/VDR Collagen TGF-beta/Smad MMP JAK	Metabolic Disease Inflammation/Immunology Endocrinology
VDR agonist 4 is an orally active potent VDR agonist. VDR agonist 4 exerts VDR-dependent antifibrotic activity by regulating multiple fibrosis-related genes to suppress α-SMA and collagen I production, thereby inhibiting hepatic stellate cell (HSC) activation. VDR agonist 4 improves CCl₄ (HY-RS16594)-induced hepatic fibrosis in mice. VDR agonist 4 can be used for liver fibrosis research .

HY-122179

NUCC-555	TGF-β Receptor	Inflammation/Immunology
NUCC-555 is an activin antagonist. NUCC-555 interacts with Trp25, Trp28, Phe55, Tyr93, Lys103, and Asn107 in the Activin A binding pocket. NUCC-555 blocks Activin A-mediated hepatic stellate cells (HSCs) activation. NUCC-555 promotes liver regeneration and halts fibrosis progression in chronic liver disease models. NUCC-555 inhibits Activin A-mediated ovarian cell proliferation. NUCC-555 decreases FSH levels in ovariectomized mice .

HY-117947

(R)-OR-S1	Histone Methyltransferase	Cancer
(R)-OR-S1 is an isomer of OR-S1. The dual ZH1/2 inhibitors OR-S1 and OR-S2 exhibit strong inhibitory activity against both EZH1 and EZH2. OR-S1 and OR-S2 are highly selective methyltransferase inhibitors against EZH1 and EZH2, and they have very similar molecular features. Therefore, we investigated the effect of OR-S1 on acute myeloid leukemia (AML). We found that OR-S1 was able to induce cell differentiation and apoptosis in AML cells. These findings encouraged us to investigate whether functional LT-HSCs could survive PRC2-targeted therapy with OR-S1 or OR-S1 combined with cytarabine. The results showed that OR-S1 did not cause significant myelosuppression, and BM cells treated with the combination therapy were able to undergo normal hematopoiesis even 4 months after treatment. Therefore, temporary inhibition of EZH1 and EZH2 is clinically tolerable, making this combination therapy suitable for AML patients. AML is generally believed to originate from myeloid progenitor cells that inherit a large number of biological properties.

HY-100791R

NSC23005 sodium (Standard)	Others Reference Standards	Cancer
NSC23005 (sodium) (Standard) is the analytical standard of NSC23005 (sodium) (HY-100791). This product is intended for research and analytical applications. NSC23005 sodium is a novel and effective p18 inhibitor (ED50=5.21 nM) in promoting Hematopoietic stem cells (HSCs) expansion in both murine and human models.

HY-N17771

(6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate	Endogenous Metabolite	Metabolic Disease
(6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate is a selective α-glucosidase inhibitor (IC₅₀=10.53 μg/mL) with anti-hepatic fibrosis and anti-diabetic properties. It also inhibits the growth of mouse hepatic stellate cells (t-HSC/Cl-6) with an IC₅₀ of 109.2 μg/mL. (6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate can be isolated from the ester derivatives of Impatiens balsamina L. flowers. (6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate can be used in research related to hepatic fibrosis and type 2 diabetes.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N17771

(6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate	Structural Classification Impatiens balsamina Linn. Balsaminaceae Phenols Polyphenols Plants Source Classification	Endogenous Metabolite
(6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate is a selective α-glucosidase inhibitor (IC₅₀=10.53 μg/mL) with anti-hepatic fibrosis and anti-diabetic properties. It also inhibits the growth of mouse hepatic stellate cells (t-HSC/Cl-6) with an IC₅₀ of 109.2 μg/mL. (6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate can be isolated from the ester derivatives of Impatiens balsamina L. flowers. (6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate can be used in research related to hepatic fibrosis and type 2 diabetes.

Cat. No.	Product Name	Chemical Structure

HY-10046S

Plerixafor-d4
Plerixafor-d₄ is the deuterium labeled Plerixafor. Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC₅₀ of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC₅₀ of 1-10 nM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks